Vanda Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Investigational Therapy for Charcot-Marie-Tooth Disease Type 2S

Rhea-AI Summary

Vanda Pharmaceuticals (Nasdaq: VNDA) announced that the FDA granted Rare Pediatric Disease Designation to VCA-894A, an investigational antisense oligonucleotide for Charcot-Marie-Tooth disease type 2S (CMT2S). CMT2S is a serious, progressive, ultra-rare pediatric neuropathy with estimated prevalence under 1 in 1,000,000 worldwide.

The designation may qualify a future approved application for a priority review voucher and highlights significant unmet need in affected children.

Positive

• FDA Rare Pediatric Disease Designation granted for VCA-894A targeting CMT2S
• Potential eligibility for a priority review voucher upon future product approval
• Regulatory recognition of CMT2S as a serious, life-threatening pediatric rare disease
• Supports development of an ASO therapy for an ultra-rare CMT2S genetic variant

Negative

• None.

News Market Reaction – VNDA

+2.97%

1 alert

+2.97% Session close to close

$373.44M Market Cap

0.8x Rel. Volume

In the Jul 8 session, VNDA gained 2.97%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The FDA’s Rare Pediatric Disease Designation for VCA-894A in ultra-rare CMT2S, with prevalence under...

Analysis

The FDA’s Rare Pediatric Disease Designation for VCA-894A in ultra-rare CMT2S, with prevalence under 1 in 1,000,000, adds to Vanda’s regulatory momentum, while an effective $200,000,000 shelf and moderate short interest remain key overhangs to monitor.

Key Figures

Disease prevalence: <1 in 1,000,000 worldwide

1 metrics

Disease prevalence <1 in 1,000,000 worldwide Estimated prevalence of CMT2S

Historical Context

5 past events · Latest: May 27 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
May 27	orphan designation	Positive	+3.9%	Japan granted orphan drug designation for imsidolimab in generalized pustular psoriasis.
May 07	conference participation	Neutral	-1.7%	Company scheduled participation in several May 2026 healthcare investor conferences.
May 06	Q1 2026 earnings	Neutral	-14.1%	Reported Q1 2026 results with higher Fanapt sales and updated full-year revenue guidance.
May 04	product launch	Positive	+8.0%	Announced U.S. commercial availability of NEREUS for motion sickness with defined pricing.
May 01	product launch	Positive	+8.0%	Detailed initial U.S. launch and pricing of NEREUS following December 2025 FDA approval.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent history shows Vanda often posting gains on positive regulatory or product milestones, while reactions to other updates are more mixed.

Key Terms

antisense oligonucleotide, rare pediatric disease designation, orphan products, priority review voucher, +2 more

6 terms

antisense oligonucleotide medical

"VCA-894A, Vanda's investigational antisense oligonucleotide therapy for the treatment"

An antisense oligonucleotide is a small piece of synthetic genetic material designed to attach to specific molecules in the body’s cells, effectively blocking or modifying how genes are expressed. This technology is important because it can be used to develop targeted treatments for certain diseases, which may influence the value of biotech companies and the broader healthcare sector. Its development reflects advances in personalized medicine and gene-based therapies.

rare pediatric disease designation regulatory

"FDA has granted Rare Pediatric Disease Designation to VCA-894A, Vanda's investigational"

A rare pediatric disease designation is an official regulatory status given to a drug or therapy that targets a serious or life‑threatening condition primarily affecting children and is uncommon in the population. It matters to investors because the status often brings financial and development perks — such as tax credits, reduced fees, faster review and periods of market protection — which can lower costs, speed approval and improve the commercial outlook; think of it as a VIP pass that makes bringing a scarce, child‑focused treatment to market easier and potentially more profitable.

orphan products regulatory

"The designation was granted by the FDA's Office of Orphan Products Development"

Medicines or medical products developed to treat rare diseases that affect only a small number of patients; they often receive special regulatory status and incentives because traditional market demand is low. For investors this matters because those incentives — such as faster review, market exclusivity, and financial credits — can change a product’s potential revenue and risk profile, much like a niche product with premium pricing and protection from competition.

priority review voucher regulatory

"may become eligible to receive a priority review voucher upon approval of a qualifying"

A priority review voucher is a transferable regulatory incentive that lets a company move a future drug or device application to the front of the review line, shortening the review period by several months. For investors it matters because the voucher can speed up market access for a high-value product or be sold to other companies for significant cash, acting like a tradable fast-pass that can accelerate revenue or create immediate financial upside.

neuromuscular disorder medical

"CMT2S is an inherited neuromuscular disorder that progressively leads to muscle weakness"

A neuromuscular disorder is a group of medical conditions that affect the nerves controlling muscles or the muscles themselves, impairing movement, strength, coordination, or basic functions like breathing and swallowing. For investors, these conditions matter because their severity, prevalence, and treatment options shape the size of potential markets, the design and risk of clinical trials, regulatory pathways, and the value of companies developing diagnostics, therapies, or medical devices — like a problem with a machine’s wiring or motors that determines what fixes are needed and how costly they will be.

neuropathy medical

"CMT2S is a devastating inherited neuropathy for which patients and families have limited"

Damage or dysfunction of the nerves that carry signals between the brain, spinal cord and the rest of the body, often causing numbness, tingling, weakness or pain like a frayed electrical wire. It matters to investors because neuropathy drives demand for diagnostics, therapies and medical devices, influences healthcare costs and can shape the commercial and regulatory prospects of drugs or technologies aimed at preventing, diagnosing or treating nerve damage.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WASHINGTON, July 7, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to VCA-894A, Vanda's investigational antisense oligonucleotide therapy for the treatment of Charcot-Marie-Tooth disease, axonal, type 2S (CMT2S), a rare, serious, and progressive inherited neurological disorder. The designation was granted by the FDA's Office of Orphan Products Development and Office of Pediatric Therapeutics.

VCA-894A is being developed for a patient who was first diagnosed at an early age with a rare subtype of Charcot-Marie-Tooth (CMT) disease known as CMT2S.¹ CMT2S is an inherited neuromuscular disorder that progressively leads to muscle weakness and loss of motor function, and has an estimated prevalence of less than 1 in 1,000,000 worldwide.² VCA-894A's therapeutic target is a unique variant of CMT2S not yet observed in any other patient. The severity and clinical presentations of CMT2S are influenced by the diverse genetic variants associated with CMT disease.

The FDA determined that CMT2S qualifies as a rare pediatric disease because it is a serious or life-threatening condition whose manifestations primarily affect individuals from birth through 18 years of age and it meets the statutory definition of a rare disease.

"CMT2S is a devastating inherited neuropathy for which patients and families have limited treatment options," said Mihael H. Polymeropoulos, M.D., President, Chief Executive Officer and Chairman of Vanda. "The FDA's Rare Pediatric Disease Designation recognizes the significant unmet medical need in this patient population and supports our efforts to develop a potentially transformative therapy for patients affected by this rare disease."

CMT2S is a rare genetic disorder characterized by chronic progressive sensory and motor impairment that can lead to severe disability, including loss of ambulation. The FDA noted in its designation letter that the serious manifestations of the disease primarily affect pediatric patients.

The Rare Pediatric Disease Designation is intended to encourage the development of new therapies for serious or life-threatening rare diseases that primarily affect children. Under the Rare Pediatric Disease Priority Review Voucher program, a sponsor whose product ultimately meets all statutory requirements may become eligible to receive a priority review voucher upon approval of a qualifying marketing application. Eligibility for any future priority review voucher will be determined at the time of a marketing application's review and approval.

Vanda is advancing development of its investigational therapy for CMT2S and will continue to work closely with the FDA regarding the development program.

References:

1. Smieszek, S. et al. Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S. Mol Ther Nucleic Acids 36, 102479 (2025).
    
2. Charcot-Marie-Tooth disease type 2S. Orpha.net (2025). https://www.orpha.net/en/disease/detail/443073

About Vanda Pharmaceuticals Inc.

Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on X @vandapharma.

About Charcot-Marie-Tooth Disease Type 2S (CMT2S)

Charcot-Marie-Tooth disease type 2S is a rare inherited neurological disorder characterized by progressive degeneration of peripheral nerves, resulting in sensory and motor impairment. The disease can lead to significant functional limitations and disability over time.

About VCA-894A

VCA-894A is a 2'-O-methoxyethyl (MOE) phosphorothioate oligonucleotide sodium salt. VCA-894A specifically targets a cryptic splice site variant within IGHMBP2, which causes CMT2S. ASOs may have broad applicability in addressing a number of disorders, from nervous system treatments to systemic treatments.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Various statements in this press release, including but not limited to statements regarding the estimated prevalence of CMT2S, the therapeutic potential of VCA-894A for patients affected by CMT2S, a sponsor's eligibility to receive a priority review voucher, and Vanda's clinical development and regulatory plans and strategies for VCA-894A, are "forward-looking statements" under the securities laws. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Forward-looking statements are based upon current expectations and assumptions that involve risks, changes in circumstances and uncertainties. Important factors that could cause actual results to differ materially from those reflected in Vanda's forward-looking statements include, among others, the accuracy of the estimates of the prevalence of CMT2S worldwide, the efficacy of VCA-894A in the treatment of patients with CMT2S, Vanda's ability to complete the development and obtain regulatory approval of VCA-894A for the treatment of CMT2S, a product's ability to meet the statutory requirements necessary for its sponsor to become eligible to receive a priority review voucher and the ultimate receipt of the voucher, and the ability of Vanda and the FDA to continue to work closely together with regard to the VCA-894A development program. Therefore, no assurance can be given that the results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Forward-looking statements in this press release should be evaluated together with the various risks and uncertainties that affect Vanda's business and market, particularly those identified in the "Cautionary Note Regarding Forward-Looking Statements", "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Vanda's most recent Annual Report on Form 10-K, as updated by Vanda's subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov.

All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf. The information in this press release is provided only as of the date of this press release, and Vanda undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Corporate Contact:

Kevin Moran
Senior Vice President, Chief Financial Officer and Treasurer
Vanda Pharmaceuticals Inc.
202-734-3400
pr@vandapharma.com

Jim Golden / Jack Kelleher / Dan Moore
Collected Strategies
VANDA-CS@collectedstrategies.com

Follow us on X @vandapharma

View original content to download multimedia:https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-announces-fda-rare-pediatric-disease-designation-for-investigational-therapy-for-charcot-marie-tooth-disease-type-2s-302819555.html

SOURCE Vanda Pharmaceuticals Inc.

FAQ

What did Vanda (NASDAQ: VNDA) announce about VCA-894A on July 7, 2026?

Vanda announced that the FDA granted Rare Pediatric Disease Designation to VCA-894A for treating Charcot-Marie-Tooth disease type 2S. According to Vanda, this designation recognizes CMT2S as a serious, life-threatening pediatric rare disease and supports development of this investigational antisense oligonucleotide therapy.

What is VCA-894A in Vanda (VNDA)'s pipeline and which disease does it target?

VCA-894A is Vanda’s investigational antisense oligonucleotide therapy for Charcot-Marie-Tooth disease type 2S (CMT2S). According to Vanda, it targets a unique CMT2S genetic variant identified in a patient diagnosed at an early age with this rare, progressive inherited neuromuscular disorder.

What does FDA Rare Pediatric Disease Designation mean for Vanda's VCA-894A?

The FDA Rare Pediatric Disease Designation makes VCA-894A’s program eligible to seek a priority review voucher if ultimately approved. According to Vanda, a qualifying marketing application that meets all statutory requirements may receive such a voucher at the time of FDA review and approval.

Why did the FDA classify Charcot-Marie-Tooth disease type 2S as a rare pediatric disease?

The FDA determined CMT2S qualifies as a rare pediatric disease because it is serious or life-threatening and primarily affects individuals from birth through 18 years. According to Vanda, CMT2S shows chronic progressive sensory and motor impairment and can lead to severe disability, including loss of ambulation.

How rare is Charcot-Marie-Tooth disease type 2S targeted by Vanda's VCA-894A?

Charcot-Marie-Tooth disease type 2S is described as an ultra-rare inherited neuromuscular disorder with estimated prevalence under 1 in 1,000,000 worldwide. According to Vanda, the therapeutic target of VCA-894A is a unique CMT2S variant not yet observed in any other patient.

What are Vanda's next steps for developing VCA-894A for CMT2S?

Vanda plans to continue advancing development of VCA-894A and working closely with the FDA on the program. According to Vanda, the Rare Pediatric Disease Designation supports ongoing efforts to create a potentially transformative therapy for patients affected by this rare pediatric neuropathy.